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Objectives The objective of this study was to evaluate the acute hemodynamic consequences of mitral valve (MV) repair
with the MitraClip device (Abbott Vascular, Menlo Park, California).
Background Whether surgical correction of mitral regurgitation (MR) results in a low cardiac output (CO) state because of an
acute increase in afterload remains controversial. The acute hemodynamic consequences of MR reduction with
the MitraClip device have not been studied.
Methods We evaluated 107 patients with cardiac catheterization before and immediately following percutaneous MV re-
pair with the MitraClip device. In addition, pre- and post-procedural hemodynamic parameters were studied by
transthoracic echocardiography.
Results MitraClip treatment was attempted in 107 patients, and in 96 (90%) patients, a MitraClip was deployed. Successful
MitraClip treatment resulted in: 1) an increase in CO from 5.0  2.0 l/min to 5.7  1.9 l/min (p  0.003); 2) an in-
crease in forward stroke volume (FSV) from 57  17 ml to 65  18 ml (p  0.001); and 3) a decrease in systemic
vascular resistance from 1,226  481 dyn·s/cm5 to 1,004  442 dyn·s/cm5 (p  0.001). In addition, there was left
ventricular (LV) unloading manifested by a decrease in LV end-diastolic pressure from 11.4  9.0 mm Hg to 8.8 
5.8 mm Hg (p  0.016) and a decrease in LV end-diastolic volume from 172  37 ml to 158  38 ml (p  0.001).
None of the patients developed acute post-procedural low CO state.
Conclusions Successful MV repair with the MitraClip system results in an immediate and significant improvement in FSV, CO,
and LV loading conditions. There was no evidence of a low CO state following MitraClip treatment for MR. These
favorable hemodynamic effects with the MitraClip appear to reduce the risk of developing a low CO state, a
complication occasionally observed after surgical MV repair for severe MR. (A Study of the Evalve Cardiovascular
Valve Repair System Endovascular Valve Edge-to-Edge Repair Study [EVEREST I]; NCT00209339 and EVEREST II;
NCT00209274) (J Am Coll Cardiol 2011;57:1658–65) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.043Surgical mitral valve (MV) repair to create a double orifice
valve was first performed by Alfieri in 1991 (1–3). A
recently introduced MV repair method uses a clip (Mitra-
Clip, Abbott Vascular, Menlo Park, California) in a trans-
catheter closed-chest intracardiac procedure that simulates
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April 19, 2011:1658–65 Effects of MitraClip TherapyOne of the concerns with surgical correction of MR has
been the potential increase in left ventricular (LV) afterload
owing to elimination of the low-impedance regurgitant flow
into the left atrium (LA). An increase in afterload associated
with correction of MR could impair LV systolic perfor-
mance (7–9) and may result in an acute post-operative low
cardiac output (CO) state (9–13). The significance of this
phenomenon in patients with surgically corrected MR by
valve replacement or repair is controversial because the
consequences of MR elimination are confounded by numer-
ous factors owing to the nature of open heart surgery and the
effects of cardiopulmonary bypass and cardioplegic arrest.
Because the MitraClip procedure does not require cardio-
pulmonary bypass, it provides a unique opportunity to assess
the acute hemodynamic changes solely attributable to reduc-
tion of MR. The objective of this analysis was to characterize
the impact of reduction in MR with the MitraClip therapy on
intraprocedural CO and hemodynamics.
Methods
We studied 107 patients, 55 treated in the EVEREST (A
Study of the Evalve Cardiovascular Valve Repair System
Endovascular Valve Edge-to-Edge Repair Study) phase I
feasibility trial (14), and 52 roll-in patients treated in the
EVEREST II pivotal trial, who represent the pre-
randomization experience.
Patient characteristics, echocardiographic protocol, and
procedural technique have recently been described (6,14,15).
Symptomatic patients with moderate to severe (3) or
severe (4) MR or asymptomatic patients with the same
MR severity and abnormal LV systolic function (left ven-
tricular ejection fraction [LVEF] 60% or LV end-systolic
dimension 40 mm) underwent MitraClip treatment in
accordance with the ACC/AHA guideline indications for
MR surgery (16). As shown in Table 1, MR was graded
according to the criteria of the American Society of Echo-
cardiography (17). Three of the 6 criteria listed in Table 1,
at least one of which was quantitative, had to be present for
classification of MR as severe or moderate to severe.
The procedure was performed under general anesthesia
using transesophageal echocardiography guidance and flu-
oroscopy. Vascular access was established from the femoral
vein. The MitraClip device was advanced following an
echocardiography-guided transseptal approach to the LA
and across the MV to the LV. The arms of the clip were
oriented perpendicular to the line of leaflet coaptation, the
leaflets were grasped, and the clip was closed while reduc-
tion of MR severity was assessed by Doppler echocardiog-
raphy. A second MitraClip device was placed if further
reduction of MR was needed. Transthoracic echocardio-
graphic (TTE) images were obtained using a detailed
echocardiographic protocol after face to face training of
sonographers in participating centers. All quantitative mea-
surements including regurgitant volume, regurgitant frac-
tion (RF), left ventricular end-diastolic volume (LVEDV),left ventricular end-systolic vol-
ume (LVESV), and forward
stroke volume (FSV) as well as
MR and TR grades from 1 to
4 were made at the core labo-
ratory (University of California
at San Francisco) (15).
Cardiac catheterization. All he-
modynamic measurements were
taken while the patients were
under general anesthesia. Pa-
tients were studied according to
the protocol before and within
15 min following attempted clip
deployment regardless of proce-
dural success.
Transducers were balanced by
determining zero level at the
mid-axillary line. LV peak end-
systolic and peak end-diastolic
pressures (LVEDP) were re-
ported. Arterial pressures were
measured from the femoral ar-
tery. Left atrial pressure was ob-
tained from the transseptal cath-
eter positioned in the LA or by
measurement of pulmonary cap-
illary wedge pressure (PCWP)
using a balloon-tipped Swan-
Ganz catheter. Wedge position
was verified by fluoroscopy and
phasic changes in pressure wave-
forms. The values of PCWP
were assessed at end expiration
with the balloon-tipped catheter
at steady state with the patient in
a supine position. Measurements
were based on an average of 5 cardiac cycles. Cardiac output
was determined by the Fick or thermodilution method
depending on the preference of the site (18). A low CO
state was defined as systolic blood pressure90 mmHg and
cardiac index (CI) 1.4 l/min/m2 after the procedure (12).
Abbreviations
and Acronyms
APS  acute procedural
success
CI  cardiac index
CO  cardiac output
FSV  forward stroke
volume
LA  left atrial/atrium
LV  left ventricular/
ventricle
LVEDP  left ventricular
end-diastolic pressure
LVEDV  left ventricular
end-diastolic volume
LVEF  left ventricular
ejection fraction
LVESV  left ventricular
end-systolic volume
MR  mitral regurgitation
MV  mitral valve
NYHA  New York Heart
Association
PA  pulmonary artery
PASP  pulmonary artery
systolic pressure
PCWP  pulmonary
capillary wedge pressure
PVR  pulmonary vascular
resistance
RA  right atrial/atrium
SVR  systemic vascular
resistance
TTE  transthoracic
echocardiography
Criteria for Moderate to Severeor S vere Mitral RegurgitationTable 1 Crit ria for Mod ate to Severeor Severe Mitral Regurgitation
Color flow jet may be central and large (6 cm2 or 30% of left atrial area) or
smaller if eccentric and encircling the left atrium
Pulmonary vein flow may show systolic blunting or systolic flow reversal
Vena contracta width 0.3 cm measured in the parasternal long-axis view
Regurgitant volume 45 ml/beat
Regurgitant fraction 40%
Regurgitant orifice area 0.30 cm2
Mitral regurgitation was classified as moderate to severe or severe if at least 3 of the above criteria
were present and at least 1 of those 3 was quantitative (i.e
area).., regurgitant volume, fraction, or orifice
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PSS (version 18.0, SPSS Inc., Chicago, Illinois). Contin-
ous variables are presented as means SD. Categoric data
are presented as absolute numbers or percentages. Hemo-
dynamic data before and following clip deployment were
compared using paired t test. Between-group comparison was
completed using independent t tests. The Levene’s test was
performed to assess homogeneity of variance. Chi-square test
was used for comparison of categoric data. The p values were
not adjusted for the multiple comparisons.
Results
We analyzed hemodynamic data from 107 patients. The
patient demographic and baseline clinical data are shown in
Table 2. New York Heart Association (NYHA) functional
Baseline Patient Characteristics (n  107)Table 2 Baseline Patient Characteristics (n  107)
Mean age, yrs 67 14
Male 62%
Diabetes mellitus 21%
Hypertension 69%
Chronic obstructive pulmonary disease 12%
History of congestive heart failure 53%
Atrial fibrillation 29%
NYHA functional class 2.4 0.7
NYHA functional class III/IV 46%
Tricuspid regurgitation 1.0 0.5
Mitral regurgitation etiology
Degenerative 84 (79%)
Ischemic/dilated 23 (21%)
Values are mean  SD, %, or n (%).
NYHA  New York Heart Association.
Figure 1 Flowchart Showing Results for 107 Study Patients
APS  acute procedural success; MR  mitral regurgitation.class III or IV symptoms were present in 46% of patients.
Etiology of MR was degenerative in 84 (79%) and func-
tional in 23 (21%) patients.
Figure 1 demonstrates a flow chart of patients with
attempted MitraClip implantation. One or two MitraClips
were implanted in 96 (90%) patients.
Effect of attempted MitraClip treatment on MR severity
for the entire cohort (n  107) for patients with (n  96)
and without (n  11) clip implantation. For the entire
tudy cohort (n  107), MR grade decreased significantly
rom 3.3  0.7 to 1.7  0.9 (p  0.001) and MR was
educed to 2 in 79 (74%) patients (Tables 3 and 4).
nvasive hemodynamics for the entire cohort (n  107).
he CO increased from 5.0 2.0 l/min to 5.76 1.9 l/min
p  0.003) and an increase in CI increased from 2.7  1.0
/min to 3.0  1.0 l/min (p  0.003) (Table 3). Improve-
ent in CO and CI correlated with having a lower baseline
I prior to successful reduction in MR with the MitraClip
r  0.5, p  0.001). In patients with APS, mean systemic
ystolic arterial pressure increased from 109 20 mmHg to
13 21 mmHg (p 0.049); however, diastolic and mean
ressures remained unchanged. This hemodynamic response
ith an increase in mean CO and unchanged mean systemic
rterial pressures resulted in a significant reduction in calcu-
ated systemic vascular resistance (SVR) from 1,253  529
yn·s/cm5 to 1,058  475 dyn·s/cm5 (p  0.001). The
VEDP decreased from 11.0  8.6 mm Hg to 8.8  6.0
mm Hg (p  0.016), and RA pressure increased slightly
from 8.31  4.7 mm Hg to 9.3  5.6 mm Hg (p  0.003).
There was no change in PASP, mean PCWP, and pulmo-
nary vascular resistance (PVR). In addition, there was a
nonsignificant opposite trend from 20.9 12.8 l/min/m2 to
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April 19, 2011:1658–65 Effects of MitraClip Therapy18.7  8.5 mm Hg, p  0.098). None of the study patients
eveloped acute low CO state after transcatheter MV repair.
oninvasive hemodynamics for the entire cohort (n 107).
TE at discharge demonstrated an increase in FSV (57 17 ml
s. 65 18ml, p 0.001) and a reduction in regurgitant volume
52 20 ml vs. 30 20 ml, p 0.001, and in RF 46 14% vs.
30 15%, p 0.001. In addition, therewas a reduction inLVEF
(60 8% vs. 56 9%, p 0.001) associated with a reduction in
VEDV (172 37 ml vs. 158 38 ml, p 0.001), while there
as no change in LVESV (p  NS).
ffect of clip implantation on MR severity (n  96).
inety six (90%) of the 107 patients who underwent
mplantation of a MitraClip experienced reduction of MR
rade of the same magnitude as entire study cohort, in this
roup of patients with a MitraClip, MR grade reduced from
.3  0.7 l/min to 1.6  0.8 l/min, p  0.001.
ffect of MitraClip implantation on invasive hemo-
ynamics (n  96). There was an increase in CO from 5.0
2.0 l/min to 5.6  1.9 l/min, p  0.003 and CI from 2.6
1.0 l/min to 3.0  1.0 l/min, p  0.002, an increase in
ystemic systolic BP (109 20 mmHg vs. 114 20 mmHg,
All Patients (N  107)Table 3 All Patients (N  107)
n
Immediate invasive assessments
Cardiac output 80
Cardiac index 78
LV peak systolic pressure 80
LV end-diastolic pressure 79
Atrial PCWP 76
Ventricular PCWP 77
Mean PCWP 90
PAP systole 92
PAP diastole 91
PAP mean 90
RAP 80
SAP systole 92
SAP diastole 92
SAP mean 83
Systemic vascular resistance 67
Pulmonic vascular resistance 74
Baseline vs. 24-h echo assessments
MR grade 96
MR regurgitant volume 72
MR regurgitant fraction 72
LV ejection fraction (%) 90
Heart rate 81
Forward stroke volume 82
Systolic arterial pressure 98
Diastolic arterial pressure 98
LV end-diastolic volume 91
LV end-systolic volume 90
LV end-diastolic diameter 87
LV end-systolic diameter 91
Values are mean  SD.
LV left ventricular; MRmitral regurgitation; PAP pulmonary a
arterial pressure. 0.034), and an associated reduction in SVR (1,259 531 fyn·s/cm5 vs. 1,059  479 dyn·s/cm5, p  0.001). The LV
DP decreased (10.8 8.8 vs. 8.8 6.0 mmHg, p 0.026),
hile RA pressure increased (7.9  4.7 mm Hg vs. 9.1  5.7
m Hg, p  0.02). Similarly, there was a trend for reduction
n the ventricular “v” wave of PCWP tracing from 20.1 12.2
m Hg to 17.9  7.6 mm Hg, p  0.098 and no significant
change in the remainder of the hemodynamic variables.
Effect of MitraClip implantation on noninvasive hemody-
namics (n 96). ByTTE, clip implantation resulted in increase
in FSV from 58 16 ml to 66 18 ml, p 0.001, a reduction
in regurgitant volume from51 20ml to 27 17ml, p 0.001,
nd RF from 46  14% to 28  15%, p  0.001. There was a
eduction in LVEF from 60  8% to 56  9%, p  0.001,
ssociated with decrease in LVEDV from 171 37ml to 157
7 ml, p  0.001, while LVESV remained unchanged.
omparison of hemodynamic and echo Doppler changes in
atients with and without successful MitraClip treatment
n  107). Eleven of 107 patients did not undergo place-
ent of MitraClip. Most of the patients who did not receive
MitraClip did not have repeat hemodynamic measure-
ents, thus, invasive hemodynamic data is only available
Pre Post p Value
5.0 2.0 5.6 1.9 0.0033
2.7 1.0 3.0 1.0 0.0025
106.7 23.5 105.2 23.9 0.5541
11.0 8.6 8.8 6.0 0.0168
16.7 8.6 16.9 7.3 0.813
20.9 12.8 18.7 8.5 0.0982
14.8 6.2 14.9 6.6 0.9307
34.4 11.2 36.0 10.5 0.1183
14.9 6.4 15.1 6.0 0.7807
23.5 11.2 23.8 7.7 0.806
8.1 4.7 9.3 5.6 0.0278
108.9 19.5 113.4 20.9 0.0486
57.6 13.8 59.3 12.6 0.2415
76.7 14.5 78.4 16.7 0.3515
1,253 529 1,058 475 0.0008
168 229 153 132 0.5992
3.3 0.7 1.7 0.9 0.0001
51.5 20.4 29.8 20.0 0.0001
45.9 13.8 29.8 15.5 0.0001
59.8 8.3 56.3 9.4 0.0001
69.5 12.4 74.7 11.7 0.0008
57.2 14.2 65.4 17.7 0.0001
129 21 120 19 0.0001
73.8 12.3 64.2 13.0 0.0001
172 37 158 38 0.0001
70.0 24.8 70.6 29.1 0.5992
5.54 0.61 5.39 0.62 0.0005
3.48 0.78 3.47 0.77 0.9093
essure; PCWP pulmonary capillary wedge pressure; SAP systolicrom a small number of patients (3 patients and CO data
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Similarly, echocardiographic stroke volume data was only
available in 6 of 11 patients who did not undergo MitraClip
procedure. As expected, MR grade did not change signifi-
cantly in this subgroup of patients without the MitraClip
(3.4  0.55 vs. 3.4  0.55, p  1.0) and similarly, no
significant change was noted in the FSV (51.0  9.1 vs.
54.5  9.3, p  0.14) as well as LVEF (58.5  90 vs. 59.3
 5.6, p  0.74). The percent delta change in FSV did not
reach statistical significance between the groups with the
MitraClip vs. without MitraClip (18.2  29% vs. 1.5 
11%, p  0.168). No comparison between group changes
was made for parameters if data was missing in majority of
patients who did not receive MitraClip.
Discussion
This is the first study to document the acute hemodynamic
effects of MitraClip treatment and of mechanical reduction of
MR under beating-heart, closed-chest conditions in humans.
Hemodynamic and Echo/Doppler Effects of MitraClip TherapyTable 4 Hemodynamic and Echo/Doppler Effects of MitraClip T
Clip Implant (n  96)
n
Pre
Mean  SD
Post
Mean  S
Immediate Invasive
Cardiac output 79 5.0 2.0 5.6 1.
Cardiac index 77 2.6 1.0 3.0 1.
LV peak systolic pressure 77 107.1 23.8 105.5 24
LV end-diastolic pressure 76 10.8 8.8 8.8 6.
Atrial PCWP 73 16.3 8.4 16.7 7.
Ventricular PCWP 74 20.1 12.2 17.9 7.
Mean PCWP 87 14.6 6.1 14.6 6.
PAP systole 87 33.8 11.0 35.5 10
PAP diastole 87 14.6 6.3 14.9 6.
PAP mean 87 23.3 11.3 23.4 7.
RAP 76 7.9 4.7 9.1 5.
SAP systole 88 109.1 19.7 114.0 20
SAP diastole 88 57.3 13.9 59.1 12
SAP mean 80 76.5 14.7 78.2 16
Systemic vascular resistance 66 1,259 531 1,059 47
Pulmonic vascular resistance 74 168 229 153 13
24 h echo assessment
MR grade 91 3.3 0.7 1.6 0.
MR regurgitant volume 68 50.7 20.1 27.4 17
MR regurgitant fraction 68 45.6 14.1 28.3 14
LV ejection fraction (%) 86 59.9 8.3 56.2 9.
Heart rate 75 69.1 11.4 74.4 11
Forward stroke volume 76 57.5 15.6 66.3 18
Systolic arterial pressure 93 129 21 121 19
Diastolic arterial pressure 93 73.9 12.4 64.8 13
LV end-diastolic volume 87 171 37 157 37
LV end-systolic volume 86 69.5 24.9 70.5 29
LV end-diastolic diameter 83 5.54 0.62 5.39 0.
LV end-systolic diameter 87 3.47 0.79 3.48 0.
Abbreviations as in Table 3.Several important and unique findings were identified.First, MitraClip treatment with a reduction of MR
severity resulted in an increase in CO and FSV with
concomitant reduction in SVR. Second, MitraClip treat-
ment and reduction in MR grade resulted in favorable
changes in LV loading conditions manifested by a decrease
in LVEDP and LVEDV.
In chronic severe MR, high pre-load and reduced after-
load (provided by low-impedance regurgitant flow into the
left atrium) result in a high total CO. However, the
magnitude of effective forward CO for any given myocardial
contractility, LV pre-load, and heart rate has been thought
to be primarily determined by the SVR. MitraClip treat-
ment, which reduces the low-impedance mitral regurgitant
flow into the left atrium, results in an immediate change in
this relationship and leads to an increase in forward flow
(CO, SV) and concomitant decrease in SVR, resulting in
improvement or near normalization of CO.
Less invasive treatments such as the MitraClip therapy
appear to be particularly beneficial in patients with an
increased risk for developing a low CO state following MV
py
p Value
No-Clip Implant (n  11)
p Valuen
Pre
Mean  SD
Post
Mean  SD
0.0025 1 6.2 N/A 4.9 N/A N/A
0.0018 1 3.5 N/A 2.8 N/A N/A
0.5429 3 95.7 13.4 96.7 24.6 0.892
0.0263 3 14.3 3.8 10.0 5.3 0.2379
0.5757 3 28.3 6.0 22.7 6.0 0.245
0.0981 3 40.3 13.3 39.0 5.0 0.8957
0.9914 3 22.7 4.5 24.3 2.5 0.671
0.0986 5 43.8 11.7 44.6 11.7 0.9297
0.7111 4 20.8 7.0 19.5 2.1 0.7538
0.919 3 30.3 2.5 35.7 4.5 0.2556
0.0236 4 12.8 3.3 12.5 1.7 0.9157
0.0356 4 104.8 12.8 100.0 30.8 0.6862
0.2284 4 65.3 8.7 64.8 17.3 0.943
0.3608 3 81.0 7.2 83.7 35.5 0.8892
0.0006 1 865 N/A 1,045 N/A N/A
0.5992 0 N/A N/A N/A
0.0001 5 3.4 0.55 3.4 0.55 N/A
0.0001 4 65.3 23.9 72.0 17.5 0.2088
0.0001 4 51.0 9.1 54.5 9.3 0.1402
0.0001 4 58.5 90.0 59.3 5.6 0.7442
0.0007 6 74.5 24.6 78.3 10.4 0.637
0.0001 6 53.3 6.8 53.9 6.6 0.8195
0.0004 5 121.2 16.1 106.4 8.7 0.1233
0.0001 5 72.6 11.9 52.8 7.6 0.0122
0.0001 4 194 35 182 53 0.4092
0.4306 4 80.0 22.2 73.0 20.2 0.3551
0.0016 4 5.80 0.36 5.40 0.73 0.1449
0.7598 4 3.63 0.54 3.18 0.65 0.078hera
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77surgery. Although surgical correction of MR has been used
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with a decrease in LV function and not infrequently an
acute low CO state ensues (12). An acute low CO state in
the immediate postoperative period is associated with an
increased risk of death and major complications such as
renal failure (10–13). Causes of diminished post-operative
cardiac function following surgical MR correction have been
associated with myocardial injury and depression of myo-
cardial contractility owing to the use of cardiopulmonary
bypass, cardioplegic arrest (21), and interruption of annular-
chordal-papillary muscle continuity in nonvalve-sparing
valve replacement (22–24). Over the last 40 years, several
strategies have been implemented to decrease the prevalence
of low CO syndrome, including revising the indications for
MV surgery, with earlier intervention recommended even in
the asymptomatic patient; improving cardioplegia solutions
and myocardial protection; wider application of MV repair
versus replacement; and subvalvular apparatus preservation
whenever repair is not possible. Although the progress in
operative care and surgical procedures have resulted in
considerable improvement in peri-operative morbidity and
mortality, the incidence of an acute CO state in selected
subgroups of patients is as high as 12% to 19% (12,25). This
risk is highest in elderly patients and in those with a history
of congestive heart failure. In this trial of MV repair with
the MitraClip system, no patient developed a peri-
procedural low CO state. Moreover, 53% of our patients
were age 70 years or older and 46% had advanced congestive
heart failure symptoms (NYHA functional class III to IV).
These findings suggest that closed-chest, off-pump MV
repair on a beating heart carries a lower risk of developing a
low CO state than previously reported with traditional MV
repair and replacement surgery.
It has been argued that an additional mechanism of
reduced LV systolic function following surgical MR reduc-
tion is the increase in afterload due to the elimination of the
low-impedance regurgitant flow into the LA. However, the
significance of this phenomenon has been controversial.
Earlier publications have promulgated the concept of an
acute increase in global LV afterload after MV replacement
or repair as a cause of LV impairment (7,8), whereas some
more recent reports have demonstrated that changes in
afterload are not uniform and in fact that afterload in some
patients may even decrease as a result of surgical correction
of MR (26,27). We propose that the acute hemodynamic
consequence of MR reduction is enhancement of FSV and
CO and maintenance of mean arterial pressure while the
changes seen in SVR are an adjustment to these hemody-
namic changes.
The distinct effect of MitraClip treatment and its MR
reduction on LV and LA hemodynamics are also intriguing.
LVEDP and LVEDV after clip implantation fall, suggest-
ing that the magnitude of reduction in regurgitant flow was
substantial and sufficient to result in LV unloading.
Although reduction of regurgitant flow would be antici-
pated to have similar effects on LA and LV pressure therewas no decrease in mean PCWP, and the PCWP “v” wave
showed only a trend for reduction. The stability of the
PCWP can be explained by the mild transmitral diastolic
gradient associated with the creation of the double orifice
valve. We previously reported that, following MitraClip
treatment, the MV area was reduced from 6.0  1.3 cm2 to
3.6  1.2 cm2 and there is a small increase in the MV
diastolic gradient from 1.7  0.9 mm Hg to 4.1  2.2 mm
Hg by TTE Doppler (1.2  6.8 days following MitraClip
insertion) (28).
The LVEF decreased post-MitraClip by approximately 4
percentage points. This observation is not unique for Mi-
traClip treatment as a reduction in LVEF of comparable
magnitude is commonly observed following surgical treat-
ment MR and is attributed to reduction of retrograde flow
to the left atrium (29). Despite the reduction in total LVEF,
the effective LVEF has increased as evidenced by an
increase in forward stroke volume. Of note, the LVESV did
not change, but LVEDV showed a statistically significant
reduction, so that LVEF decreased slightly but not clinically
significant. It is likely that the lack of change in the LVESV
reflects preserved LV function and that LVEDV reduction
is associated with the reduction in MR and consequently
less transmitral flow filling the LV, resulting in a smaller
LVEDV. The stroke volume goes up because more blood is
ejected forward due to reduction in MR. The small rise in
right atrial pressure may be related to intravenous hydration
during the procedure, which is performed under general
anesthesia. However, a contribution from the newly created
left to right shunt after the transeptal puncture, which is
requisite for this procedure, cannot be excluded.
The MitraClip therapy provides a unique model to study
the acute hemodynamic changes secondary to MR reduc-
tion in isolation from the other changes that occur with
open heart surgery. This allows for the assessment of the
pure hemodynamic consequences of reduction of regurgi-
tant flow. Patients who undergo the MitraClip procedure
were not subjected to the hemodynamic insults related to
thoracotomy, cardioplegic arrest and cardio-pulmonary by-
pass, well known to cause transient ventricular dysfunction
and abnormal septal motion (30,31). Additionally surgery is
often associated with major changes in loading conditions
(32,33), rhythm disturbances (34,35), the use of vasoactive
medications in the post-operative period, and post-
operative bleeding.
Study limitations. All hemodynamic and CO data were
obtained under general anesthesia before and after Mitra-
Clip placement. It is not possible to completely dissociate
the effects of anesthesia from the effects of clip implantation
on the hemodynamics. The role of intravenous hydration
during this procedure on patients who had been fasting
overnight and possibly became relatively hypovolemic at the
beginning of the procedure is uncertain. It is, however,
possible that in hypovolemic patients, intraprocedural intra-
venous hydration accounted in part for the rise in mean
PCWP and systolic PA pressure following successful reduc-
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volume data was not available at the time of cardiac
catheterization. Heart rate data for the purpose of the
original EVEREST study were not required to be collected
at the same time as determination of CO. Consequently,
stroke volume could not be reliably calculated retrospec-
tively from the nonsimultaneous CO and heart rate data.
Therefore, the FSV data were obtained from the screening
and pre-discharge TTE studies. However, it is reassuring
that the effect of MitraClip treatment on FSV by the echo
Doppler parameters and CO by thermo dilution or Ficks
method are concordant. Namely, with post-MitraClip im-
plantation, there is an increase in both CO and FSV.
Conclusions
The reduction in the regurgitant volume achieved by Mitra-
Clip treatment results in an acute augmentation in forward
CO and FSV and maintenance of mean systemic arterial
blood pressure. In addition, MitraClip treatment promotes
LV unloading by reducing LVEDP and LVEDV. These
hemodynamic effects are likely to reduce the risk of acute
low CO state immediately after reduction in MR with the
MitraClip device. These findings may have especially im-
portant implications for the use of the MitraClip therapy in
patients with a high risk for a post-operative low CO state.
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